-
Introduction to tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu, CAS: 1118767-16-0
January 16,2026.
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is a specialized chemical side-chain intermediate crucial for the synthesis of the anti-diabetic drug Semaglutide. Basic Chemical Information Item Information CAS Numbe...
View More
-
Introduction to SNAC as a Pharmaceutical Excipient
January 27,2026.
What is SNAC? SNAC (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) is a synthetically produced pharmaceutical excipient classified as an intestinal permeation enhancer. Its primary function is to im...
View More
-
Accelerate Radiopharmaceutical R&D with a Complete Precursor Building Block Platform
May 11,2026.
At Sinopeg, we’re dedicated to empowering radiopharmaceutical innovators with a comprehensive library of precursor building blocks covering all three core modules of radiopharmaceutical molecules: Lig...
View More
-
Unlocking in vivo CAR-T therapy with DSPE-PEG-MAL - A chemical bridge to the next generation of cell treatment
May 21,2026.
The revolution of in vivo CAR-T is here. After decades of impressive but logistically challenging ex vivo CAR-T, 2025 marks the turning point-Capstan’s CPTX2309 entered Phase I, and AbbVie acquired Ca...
View More
-
R&D News | Sinopeg’s Key Excipient for Nucleic Acid Drug Delivery, DSPE-PEG-MAL, Reaches Another Milestone – CDE Filing Completed!
June 8,2026.
Recently, Sinopeg’s LNP lipid excipient product, DSPE-PEG-MAL(NH4+)-2K, has successfully completed pharmaceutical excipient filing with the Center for Drug Evaluation (CDE) of the National Medical Pro...
View More
Business WeChat
